| Oryzon Genomics | Oryzon is a public clinical stage biopharmaceutical company developing epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and Oncology. Oryzon team is composed by +50 highly qualified professionals located in Barcelona, Boston, NYC and San Diego. |
| Avalyn Pharma | Avalyn is a biopharma company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. Avalyn’s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases. |
| PHD Biosciences | PHD OncoDerm LLC (PHD) is clincial stage company developing a uracil topical cream to prevent hand-foot syndrome induced by capecitabine chemotherapy. |
| ENYO Pharma | ENYO Pharma is developing Vonafexor, a synthetic non-steroidal, non-Bile Acid, highly selective, orally bioavailable FXR agonist with sustained target engagement that is currently in Phase II clinical development with potential indications for the treatment of kidney diseases associated with NASH, chronic Hepatitis B/D (cHBV, cHDV) and of non-alcoholic steato-hepatitis (NASH). |
| Innova Theraepeutics | Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein that is highly expressed in various solid cancers and shown to correlate with patient outcome. The lead humanized mAb has been selected and is designated as IVT-8086. Innova’s platform technology is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer and pancreatic cancer. The opportunity for this anticancer therapy as a monotherapy and in combination with other chemotherapy agents will expand across other solid tumors. The focus on pediatric osteosarcoma as one of the initial targets will allow a fast-regulatory approval. Osteosarcoma is a rare disease which was granted both orphan designation and rare pediatric disease designation from the FDA, which will expedite the regulatory approval timeline including the opportunity to obtain a Rare Pediatric Disease priority review voucher. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged, with revenue ranging between $80M and $350M. |
| MedAbome, Inc. | MedAbome, Inc. is a biopharmaceutical discovery company located in San Francisco Bay Area (Fremont, California). We focus on the discovery and development of innovative therapeutic monoclonal antibodies (mAbs) and immunotherapy technologies for the treatment of major human cancer and non-cancer diseases, such as cancers (AML, gastric cancer, TNBC, pancreatic cancer, etc.), infectious diseases, inflammatory and autoimmune diseases, etc. By utilizing a combination of high-throughput (HT) hybridoma generation and live-cell high-throughput screening (LC-HTS) technologies, we are creating First-in-Class (FIC) therapeutic antibody candidates to meet the urgent demands of the patients and the global healthcare markets. |
| OneThree Biotech | OneThree Biotech is a clinically validated, biology-driven artificial intelligence (AI) company focused on using its proprietary AI platform in combination with systems biology to understand the mechanisms that drive drug-target-disease relationships. OneThree Biotech’s proven technology platform integrates chemical, biological, and clinical data with cutting-edge computational tools to answer complex questions surrounding disease biology and drug discovery. The company’s AI platform has shown success in optimizing early-stage drug discovery and development by quickly and accurately generating new, testable insights and hypotheses. The OneThree platform has been validated across early stage drug discovery through multiple partnerships, clinical trials, and over 20 peer reviewed publications. |
BioToChina.org 